Justcurious, regarding the dose, Reach2HD are using the same dose and the same drug that demonstrated efficacy against Alzheimer's, for executive function, in half the time of this trial. I will not be surprised if they do that for the same problem in Huntington's. For this trial to be a huge success, that is all they need to demonstrate along with safety. Work in the model showed effect in chorea and reduced brain cell degeneration.
Prana have identified HD as a rapid route to market and I think there is a decent chance we will see some effect within the 6 months. Imaging and even eye checks could also show up something.
The last update on April 3:
Last Patient recruited December 2012;
• Last Patient to be Dosed June, 2013;
• Results anticipated October, 2013;
I don't know if we should read anything into a late announcement for last patient dosed.
watching closely, page-75
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ATH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.4¢ |
Change
0.001(33.3%) |
Mkt cap ! $21.28M | |||
| Open | High | Low | Value | Volume |
| 0.3¢ | 0.4¢ | 0.3¢ | $570 | 149.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 12 | 13513113 | 0.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.4¢ | 130775819 | 29 |
View Market Depth
| Last trade - 15.46pm 27/09/2024 (20 minute delay) ? |
| ATH (ASX) Chart |